Biotech | November 20, 2021
Oravax and Genomma JV to commercialise Covid-19 vaccine in Mexico and Latam
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Betting big on talent, resources, and the ecosystem required for innovation and enterprise, Prime Minister Narendra Modi invited stakeholders to ideate in India, innovate in India and Make in India for the world
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
Nelarabine is in a class of medications called antimetabolites
Launching in 2022, its availability will be expanded to the global market
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
EaseVRx employs the principles of cognitive behavioural therapy and other behavioural therapy techniques for the reduction of pain and pain interference
Subscribe To Our Newsletter & Stay Updated
